Jacqueline Fidanza
Directeur des opérations chez Scale Biosciences, Inc.
Profil
Jacqueline Fidanza currently works at Scale Biosciences, Inc., as Chief Operating Officer from 2023.
Postes actifs de Jacqueline Fidanza
Sociétés | Poste | Début |
---|---|---|
Scale Biosciences, Inc.
Scale Biosciences, Inc. Medical SpecialtiesHealth Technology Scale Biosciences, Inc. is an American single-cell sequencing solutions company that aims to unlock the potential of single-cell analysis at scale by eliminating barriers to discovery. The private company has R & D facilities in Menlo Park, CA and another location that is not specified. The company is located in the US. Scalebio is financed by leading life sciences tools investors Arch Venture Partners, BNG, and Tao Capital. The company's multidisciplinary team of scientists and technologists has combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics. Discover how their single-cell sequencing technology enables scalable sample indexing, cell throughput, and multi-omics analysis. | Directeur des opérations | 01/07/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Scale Biosciences, Inc.
Scale Biosciences, Inc. Medical SpecialtiesHealth Technology Scale Biosciences, Inc. is an American single-cell sequencing solutions company that aims to unlock the potential of single-cell analysis at scale by eliminating barriers to discovery. The private company has R & D facilities in Menlo Park, CA and another location that is not specified. The company is located in the US. Scalebio is financed by leading life sciences tools investors Arch Venture Partners, BNG, and Tao Capital. The company's multidisciplinary team of scientists and technologists has combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics. Discover how their single-cell sequencing technology enables scalable sample indexing, cell throughput, and multi-omics analysis. | Health Technology |